- Preclinical data showed synergistic and additive effects of combination imetelstat and ruxolitinib - Study intended to explore potential for disease modification with imetelstat in earlier, ...
Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback